Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Garrido, A.
  • Hoyos Colell, Montserrat
  • Arnan, Montserrat
  • Vives Polo, Susana
  • Oñate, Guadalupe
  • Bataller Torralba, Alex
  • Salamero, Olga
Prognostic impact; Mutation; Acute myeloid leukemia, Impacte pronòstic; Mutació; Leucèmia mieloide aguda, Impacto pronóstico; Mutación; Leucemia mieloide aguda, The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD−; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention., This work was supported in part by the Biomedical Research Institute (IIB Sant-Pau) and the José Carreras Leukemia Research Institute as well as grants from the Catalan Government (PERIS SLT002/16/0043 and AGAUR 2017 SGR 139) and the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain (PI17/01246, PI20/01621 and CM20/00061).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Bataller, Alex|||0000-0002-6085-2745
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Arnan, Montserrat
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Coll, Rosa|||0000-0003-0560-1254
  • Tormo, Mar|||0000-0001-9622-1649
  • Sampol, Antonia|||0000-0001-7465-6203
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Salamero, Olga|||0000-0003-3237-0025
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Bargay, Joan|||0000-0002-6739-3916
  • Aljarilla, Alba
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Pratcorona, Marta|||0000-0001-6375-596X
The negative prognostic impact of internal tandem duplication of FLT3 (FLT3- ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML- NPM1) is restricted to those with a higher FLT3 -ITD allelic ratio (FLT3 high ; ≥0.5) and considered negligible in those with a wild-type (FLT3 WT)/low ITD ratio (FLT3 low). Because the comutation of DNMT3A (DNMT3A mut) has been suggested to negatively influence prognosis in AML- NPM1, we analyzed the impact of DNMT3A mut in FLT3 -ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML- NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A mut status did not have a prognostic impact, with comparable overall survival (P =.2). Prognostic stratification established by FLT3 -ITD (FLT3 WT = FLT3 low.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide

  • Esquirol, Albert|||0000-0002-6062-5980
  • Pascual, Maria Jesus
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Herruzo, Beatriz
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Pérez, Ariadna
  • Torio, Alberto
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Cuesta, Marian
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Sierra, Jorge|||0000-0002-7966-0356
One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impact on each transplantation outcome studied in multivariate analysis allowed for better stratification of patient outcomes. Thus, the 3-year overall survival (OS) in patients with 0, 1, 2, and 3 unfavorable scores was 86%, 56%, 36%, and 24%, respectively. Nonrelapse mortality (NRM) was negatively impacted by the EBMT-RS and the HCT-CI-age score (3-year NRM in patients with 0, 1, and 2 unfavorable scores was 12%, 33%, and 43%, respectively), whereas the EBMT-RS and the rDRI had an impact on the 3-year relapse incidence (8%, 18%, and 41% in patients with 0, 1, and 2 unfavorable scores, respectively). In conclusion, our study shows that combining 2 or 3 of these well-defined pretransplantation scores improves the ability to predict transplantation outcomes in the setting of haploSCT with PTCy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Garrido, A.
  • Hoyos Colell, Montserrat
  • Arnan, Montserrat
  • Vives Polo, Susana
  • Oñate, Guadalupe
  • Bataller Torralba, Alex
  • Salamero, Olga
Prognostic impact; Mutation; Acute myeloid leukemia, Impacte pronòstic; Mutació; Leucèmia mieloide aguda, Impacto pronóstico; Mutación; Leucemia mieloide aguda, The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD−; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention., This work was supported in part by the Biomedical Research Institute (IIB Sant-Pau) and the José Carreras Leukemia Research Institute as well as grants from the Catalan Government (PERIS SLT002/16/0043 and AGAUR 2017 SGR 139) and the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain (PI17/01246, PI20/01621 and CM20/00061).